CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Bevacizumab and granulocyte-macrophage colony-stimulating factor in pretreated patients with metastatic solid malignancies
DOI 10.1055/s-0028-1088676
Bibliografische Angaben
Nachweis in CareLit
Autor:innenCM Kurbacher, S Schäfer, G Wessling, JA Kurbacher, PN Arenz, M Schmidt
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Bevacizumab (BEV) is an important anti-angiogenetic agent which may also stimulate the generation of dendritic cells (DC). This effect may be further potentiated by GM-CSF. This trial was initiated to study BEV+GM-CSF in 21 patients (pts) with metastatic solid malignancies: ovarian cancer, n=8; breast cancer, n=5; primary peritoneal carcinoma, n=3; hormone-refractory prostate cancer, n=2; others, n=3. All pts have b…
Zitieren
Zitierempfehlung
CM Kurbacher, S Schäfer, G Wessling, JA Kurbacher, PN Arenz, M Schmidt (2008) Bevacizumab and granulocyte-macrophage colony-stimulating factor in pretreated patients with metastatic solid malignancies. Geburtshilfe und Frauenheilkunde (09). https://doi.org/10.1055/s-0028-1088676
Mit CareLit weiterarbeiten